Finance

Protein-based diagnostic products developer announces annual revenues of $2,818,000

Published in Cancer Weekly, March 7th, 2006

Matritech (MZT) reported revenues for the fourth quarter of 2005 were $2,818,000 compared with $2,432,000 for the fourth quarter of 2004, an increase of 16%.

Revenue recognized from sales of the NMP22 BladderChek Test increased 38% during the quarter to $2,254,000 compared to $1,632,000 in the fourth quarter of 2004. Overall product sales for the fourth quarter of 2005 were $2,776,000 compared with $2,382,000 for the fourth quarter of 2004. NMP22 BladderChek Test sales accounted for approximately 90% of sales in the NMP22 product line.

The company reported a loss from operations of $1,795,000 for the fourth quarter of 2005 compared with a loss from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-03-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry